News Trodelvy gets EU nod for first-line triple-neg breast cancer A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.
News Datroway joins Trodelvy for frontline TNBC in the EU AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
News Gilead, MSD share data on once-weekly oral HIV treatment Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.
News Trial of Bundibugyo Ebola drugs starts in DRC Patients are now being enrolled in a trial of two potential therapies for Bundibugyo Ebola, Mapp's MBP134 and Gilead's remdesivir, says WHO.
News Ibrance cleared in US for 'double-positive' breast cancer Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.
News Astellas' Padcev and Gilead's Trodelvy grab key EU approvals New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
